Korsana Biosciences: General Atlantic holds 6.8%

General Atlantic-affiliated funds report a 6.8% beneficial stake in Korsana Biosciences, largely via shares and a sizable pre-funded warrant position.

Rhea-AI Filing Summary

Korsana Biosciences, Inc. (CYCN) has a new large shareholder group led by General Atlantic investment entities, which together report beneficial ownership of 3,201,131 shares of common stock, representing 6.8% of the company. The position is held through General Atlantic (KB), L.P., which owns 1,366,242 shares of common stock and a Pre-Funded Warrant to purchase an additional 1,834,889 shares.

The 6.8% ownership is calculated against an aggregate base of 47,376,314 shares, including shares issuable upon warrant exercise. Multiple General Atlantic partnerships and co-investment vehicles may be deemed to share voting and dispositive power, and warrant exercises are limited by a 9.99% beneficial-ownership blocker.

Key Figures

Beneficially owned shares: 3,201,131 shares Common shares held: 1,366,242 shares Pre-Funded Warrant underlying shares: 1,834,889 shares +4 more

7 metrics

Beneficially owned shares 3,201,131 shares Shares of Korsana Biosciences common stock beneficially owned by General Atlantic reporting group

Common shares held 1,366,242 shares Common stock of Korsana Biosciences owned of record by General Atlantic (KB), L.P.

Pre-Funded Warrant underlying shares 1,834,889 shares Shares of common stock issuable upon exercise of the Pre-Funded Warrant held by General Atlantic (KB), L.P.

Percent of class 6.8% Ownership percentage of Korsana Biosciences common stock attributed to the reporting persons

Aggregate shares for ownership base 47,376,314 shares Total shares used for percentage calculation, including shares issuable upon warrant exercise

Shares outstanding (excluding warrant) 45,541,425 shares Common shares reported issued and outstanding as of September 8, 2026

Beneficial ownership blocker 9.99% Maximum beneficial ownership allowed before pre-funded warrant exercises are blocked

Key Terms

Pre-Funded Warrant, beneficially own, blocker provision, Schedule 13G, +1 more

5 terms

Pre-Funded Warrant financial

"and a pre-funded warrant (the "Pre-Funded Warrant") to purchase 1,834,889"

A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.

beneficially own financial

"each of the Reporting Persons may be deemed to beneficially own the shares"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

blocker provision financial

"subject to a blocker provision that will prohibit the Reporting Persons from exercising"

Schedule 13G regulatory

"This Statement is being filed on behalf of each of the following persons"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

percent of class financial

"(b) | Percent of class: The percentages used herein are calculated based upon"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake do General Atlantic entities report in Korsana Biosciences (CYCN)?

General Atlantic-affiliated funds report beneficial ownership of 3,201,131 shares of Korsana Biosciences common stock, representing 6.8% of the company’s common shares, including shares issuable upon exercise of a pre-funded warrant.

How many Korsana Biosciences (CYCN) shares does General Atlantic (KB), L.P. hold?

General Atlantic (KB), L.P. holds 1,366,242 shares of Korsana Biosciences common stock and a Pre-Funded Warrant to purchase 1,834,889 additional shares of common stock.

What percentage of Korsana Biosciences (CYCN) does the reported 3,201,131 shares represent?

The 3,201,131 shares beneficially owned by the General Atlantic group represent 6.8% of Korsana Biosciences’ common stock, based on an aggregate of 47,376,314 shares including shares underlying the pre-funded warrant.

What is the blocker provision on the pre-funded warrant held in Korsana Biosciences (CYCN)?

The pre-funded warrant held by General Atlantic (KB), L.P. includes a 9.99% beneficial ownership blocker that prohibits exercise if it would cause any reporting person to beneficially own more than 9.99% of Korsana’s outstanding common stock.

How many Korsana Biosciences (CYCN) shares were outstanding for the 6.8% calculation?

The 6.8% ownership is based on 47,376,314 shares of Korsana Biosciences common stock, consisting of 45,541,425 shares reported outstanding plus 1,834,889 shares issuable upon exercise of the pre-funded warrant.

Which entities are part of the General Atlantic group holding CYCN shares?

The reporting group includes General Atlantic, L.P., multiple General Atlantic Partners and GAP Coinvestment entities, Bermuda and Luxembourg partnerships and LLCs, with General Atlantic (KB), L.P. holding the shares and pre-funded warrant of Korsana Biosciences.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 07:20 PM Accepted by SEC EDGAR 09/18/2026 - 07:20 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Korsana Biosciences, Inc.

(Name of Issuer)

Common Stock, no par value per share

(Title of Class of Securities)

23255M303

(CUSIP Number)

09/08/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

GENERAL ATLANTIC, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

General Atlantic Partners 100, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

GAP Coinvestments III, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

GAP Coinvestments IV, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

GAP Coinvestments V, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

GAP Coinvestments CDA, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

GAP Coinvestments PE Holdco, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

GAP Coinvestments PE Holdco GP, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

GAP Holdings GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

General Atlantic (SPV) GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

General Atlantic GenPar (Bermuda), L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

BERMUDA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

General Atlantic GenPar, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

General Atlantic (KB), L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

GAP (Bermuda) L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

BERMUDA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

General Atlantic (Lux) S.a r.l.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

LUXEMBOURG

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

General Atlantic GenPar (Lux) SCSp

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

LUXEMBOURG

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 23255M303

1

Names of Reporting Persons

General Atlantic Partners (Lux) SCSp

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

LUXEMBOURG

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,201,131.00
7	Sole Dispositive Power 3,201,131.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,201,131.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Korsana Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 203 CRESCENT STREET, BLDGS. #3/3A/4, SUITE 503, WALTHAM, MA 02453
Item 2.
(a)	Name of person filing: This Statement is being filed on behalf of each of the following persons (collectively, the "Reporting Persons"): (i) General Atlantic, L.P. ("GA LP"); (ii) General Atlantic Partners 100, L.P. ("GAP 100"); (iii) GAP Coinvestments III, LLC ("GAPCO III"); (iv) GAP Coinvestments IV, LLC ("GAPCO IV"); (v) GAP Coinvestments V, LLC ("GAPCO V"); (vi) GAP Coinvestments CDA, L.P. ("GAPCO CDA"); (vii) GAP Coinvestments PE Holdco, L.P. ("GAP PE Holdco"); (viii) GAP Coinvestments PE Holdco GP, L.P. ("GAP PE Holdco GP"); (ix) GAP Holdings GP, LLC ("GAP Holdings GP"); (x) General Atlantic (SPV) GP, LLC ("GA SPV"); (xi) General Atlantic GenPar (Bermuda), L.P. ("GenPar Bermuda"); (xii) General Atlantic GenPar, L.P. ("GA GenPar"); (xiii) General Atlantic (KB), L.P. ("GA KB"); (xiv) GAP (Bermuda) L.P. ("GAP Bermuda"); (xv) General Atlantic (Lux) S.a r.l. ("GA Lux"); (xvi) General Atlantic GenPar (Lux) SCSp ("GA GenPar Lux"); and (xvii) General Atlantic Partners (Lux) SCSp ("GAP Lux").
(b)	Address or principal business office or, if none, residence: The address of GA LP, GAP 100, GAPCO III, GAPCO IV, GAPCO V, GAPCO CDA, GAP PE Holdco, GAP PE Holdco GP, GAP Holdings GP, GA GenPar, GA SPV and GA KB is c/o General Atlantic Service Company, L.P., 55 East 52nd Street, 33rd Floor, New York, NY 10055. The address of GenPar Bermuda and GAP Bermuda is Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. The address of GA Lux, GA GenPar Lux and GAP Lux is 412F Route d'Esch, L-1471 Luxembourg.
(c)	Citizenship: See Row (4) of each Reporting Person's cover page.
(d)	Title of class of securities: Common Stock, no par value per share
(e)	CUSIP Number(s): 23255M303
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of September 8, 2026, the Reporting Persons owned the following number of shares of Common Stock, no par value per share (the "common stock"), of Korsana Biosciences, Inc. (the "Company"): (i) GA LP owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. (ii) GAP 100 owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. (iii) GAPCO III owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. (iv) GAPCO IV owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. (v) GAPCO V owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. (vi) GAPCO CDA owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. (vii) GAP PE Holdco owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. (viii) GAP PE Holdco GP owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. (ix) GAP Holdings GP owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. (x) GA SPV owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. (xi) GenPar Bermuda owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. (xii) GA GenPar owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. (xiii) GA KB owned of record 1,366,242 shares of common stock and a pre-funded warrant (the "Pre-Funded Warrant") to purchase 1,834,889 shares of common stock, or 6.8% of the issued and outstanding shares of common stock. (xiv) GAP Bermuda owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. (xv) GA Lux owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. (xvi) GA GenPar Lux owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. (xvii) GAP Lux owned of record no shares of common stock or 0.0% of the issued and outstanding shares of common stock. The limited partners of GA KB that share beneficial ownership of the shares of common stock held by GA KB are the following General Atlantic investment funds: GAP 100, GAP Lux, GAPCO III, GAPCO IV, GAPCO V, GAPCO CDA and GAP PE Holdco. The general partner of GA KB is GA SPV. The general partner of GAP 100 is GA GenPar. The general partner of GAP Lux is GA GenPar Lux, and the general partner of GA GenPar Lux is GA Lux. The sole shareholder of GA Lux is GenPar Bermuda. GA LP, which is controlled by the Partnership Committee of GASC MGP, LLC (the "Partnership Committee"), is the managing member of GAPCO III, GAPCO IV and GAPCO V, the general partner of GAPCO CDA and GA GenPar, and is the sole member of GA SPV. GAP Bermuda, which is also controlled by the Partnership Committee, is the general partner of GenPar Bermuda. GAP Holdings GP, which is also controlled by the Partnership Committee, is the general partner of GAP PE Holdco GP, which is the general partner of GAP PE Holdco. By virtue of the foregoing, the Reporting Persons may be deemed to share voting power and the power to direct the disposition of the shares that each owns of record. As of the date hereof, there are six members of the Partnership Committee. Each of the members of the Partnership Committee disclaims ownership of the shares of common stock reported herein except to the extent that he has a pecuniary interest therein. The name, the address and the citizenship of each of the members of the Partnership Committee as of the date hereof is attached hereto as Schedule A and is hereby incorporated by reference. Amount Beneficially Owned: By virtue of the relationship described above, each of the Reporting Persons may be deemed to beneficially own the shares of common stock indicated on row (9) on such Reporting Person's cover page included herein.
(b)	Percent of class: The percentages used herein are calculated based upon an aggregate of 47,376,314 shares of common stock, consisting of (i) 45,541,425 shares of common stock reported by the Company to be issued and outstanding as of September 8, 2026 reflected in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on September 11, 2026 and (ii) 1,834,889 shares of common stock issuable upon exercise of the Pre-Funded Warrant. The Reporting Persons' ability to exercise the Pre-Funded Warrant is subject to a blocker provision that will prohibit the Reporting Persons from exercising the Pre-Funded Warrant if such exercise would result in any of the Reporting Persons beneficially owning more than 9.99% of the outstanding shares of common stock at any time, determined in accordance with rules promulgated under the Securities Exchange Act of 1934, as amended.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Each of the Reporting Persons may be deemed to have the sole power to direct the voting of the shares of common stock indicated on Row (5) of each such Reporting Person's cover page included herein.
	(ii) Shared power to vote or to direct the vote: Each of the Reporting Persons may be deemed to share the power to direct the voting of the shares of common stock indicated on Row (6) of each such Reporting Person's cover page included herein.
	(iii) Sole power to dispose or to direct the disposition of: Each of the Reporting Persons may be deemed to have the sole power to direct the dispositions of the shares of common stock indicated on Row (7) of each such Reporting Person's cover page included herein.
	(iv) Shared power to dispose or to direct the disposition of: Each of the Reporting Persons may be deemed to share the power to direct the dispositions of the shares of common stock indicated on Row (8) of each such Reporting Person's cover page included herein.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Item 2, which states the identity of the members of the group filing this Schedule 13G.
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GENERAL ATLANTIC, L.P.

Signature:	/s/ Michael Gosk
Name/Title:	Michael Gosk, Managing Director
Date:	09/18/2026

General Atlantic Partners 100, L.P.

Signature:	/s/ Michael Gosk
Name/Title:	Michael Gosk, Managing Director of General Atlantic, L.P., the general partner of General Atlantic GenPar, L.P., its general partner
Date:	09/18/2026

GAP Coinvestments III, LLC

Signature:	/s/ Michael Gosk
Name/Title:	Michael Gosk, Managing Director of General Atlantic, L.P., its managing member
Date:	09/18/2026

GAP Coinvestments IV, LLC

Signature:	/s/ Michael Gosk
Name/Title:	Michael Gosk, Managing Director of General Atlantic, L.P., its managing member
Date:	09/18/2026

GAP Coinvestments V, LLC

Signature:	/s/ Michael Gosk
Name/Title:	Michael Gosk, Managing Director of General Atlantic, L.P., its managing member
Date:	09/18/2026

GAP Coinvestments CDA, L.P.

Signature:	/s/ Michael Gosk
Name/Title:	Michael Gosk, Managing Director of General Atlantic, L.P., its general partner
Date:	09/18/2026

GAP Coinvestments PE Holdco, L.P.

Signature:	/s/ Michael Gosk
Name/Title:	Michael Gosk, Managing Director of GAP Holdings GP, LLC, the general partner of GAP Coinvestments PE Holdco GP, L.P., its general partner
Date:	09/18/2026

GAP Coinvestments PE Holdco GP, L.P.

Signature:	/s/ Michael Gosk
Name/Title:	Michael Gosk, Managing Director of GAP Holdings GP, LLC, its general partner
Date:	09/18/2026

GAP Holdings GP, LLC

Signature:	/s/ Michael Gosk
Name/Title:	Michael Gosk, Managing Director
Date:	09/18/2026

General Atlantic (SPV) GP, LLC

Signature:	/s/ Michael Gosk
Name/Title:	Michael Gosk, Managing Director of General Atlantic, L.P., its sole member
Date:	09/18/2026

General Atlantic GenPar (Bermuda), L.P.

Signature:	/s/ Michael Gosk
Name/Title:	Michael Gosk, Managing Director of GAP (Bermuda) GP Limited, the general partner of GAP (Bermuda) L.P., its general partner
Date:	09/18/2026

General Atlantic GenPar, L.P.

Signature:	/s/ Michael Gosk
Name/Title:	Michael Gosk, Managing Director of General Atlantic, L.P., its general partner
Date:	09/18/2026

General Atlantic (KB), L.P.

Signature:	/s/ Michael Gosk
Name/Title:	Michael Gosk, Managing Director of General Atlantic, L.P., the sole member of General Atlantic (SPV) GP, LLC, its general partner
Date:	09/18/2026

GAP (Bermuda) L.P.

Signature:	/s/ Michael Gosk
Name/Title:	Michael Gosk, Managing Director of GAP (Bermuda) GP Limited, its general partner
Date:	09/18/2026

General Atlantic (Lux) S.a r.l.

Signature:	/s/ Ingrid van der Hoorn
Name/Title:	Ingrid van der Hoorn, Manager A
Date:	09/18/2026

Signature:	/s/ William Blackwell
Name/Title:	William Blackwell, Manager B
Date:	09/18/2026

General Atlantic GenPar (Lux) SCSp

Signature:	/s/ Ingrid van der Hoorn
Name/Title:	Ingrid van der Hoorn, Manager A of General Atlantic (Lux) S.a r.l., its general partner
Date:	09/18/2026

Signature:	/s/ William Blackwell
Name/Title:	William Blackwell, Manager B of General Atlantic (Lux) S.a r.l., its general partner
Date:	09/18/2026

General Atlantic Partners (Lux) SCSp

Signature:	/s/ Ingrid van der Hoorn
Name/Title:	Ingrid van der Hoorn, Manager A of General Atlantic (Lux) S.a r.l., the general partner of General Atlantic GenPar (Lux) SCSp, its general partner
Date:	09/18/2026

Signature:	/s/ William Blackwell
Name/Title:	William Blackwell, Manager B of General Atlantic (Lux) S.a r.l., the general partner of General Atlantic GenPar (Lux) SCSp, its general partner
Date:	09/18/2026

Exhibit Information

Exhibit 1 - Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.